Literature DB >> 31665363

Microenvironmental Heterogeneity Among Triple-Negative Breast Cancer Subtypes and the Promise of Precision Medicine.

Lior Z Braunstein1, Nadeem Riaz1,2.   

Abstract

Entities:  

Year:  2020        PMID： 31665363      PMCID： PMC7357316          DOI： 10.1093/jnci/djz209

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  17 in total

1.  First clinical trials of endostatin yield lukewarm results.

Authors:  Renee Twombly
Journal:  J Natl Cancer Inst       Date:  2002-10-16       Impact factor: 13.506

2.  Gene expression profiling predicts clinical outcome of breast cancer.

Authors:  Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

Review 3.  Breast Cancer Immunotherapy: Facts and Hopes.

Authors:  Leisha A Emens
Journal:  Clin Cancer Res       Date:  2017-08-11       Impact factor: 12.531

Review 4.  Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.

Authors:  Dai Fukumura; Jonas Kloepper; Zohreh Amoozgar; Dan G Duda; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2018-03-06       Impact factor: 66.675

Review 5.  The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.

Authors:  Jonathan J Havel; Diego Chowell; Timothy A Chan
Journal:  Nat Rev Cancer       Date:  2019-03       Impact factor: 60.716

Review 6.  Cancer immunotherapy using checkpoint blockade.

Authors:  Antoni Ribas; Jedd D Wolchok
Journal:  Science       Date:  2018-03-22       Impact factor: 47.728

7.  Phase I study of recombinant human endostatin in patients with advanced solid tumors.

Authors:  Roy S Herbst; Kenneth R Hess; Hai T Tran; Jennifer E Tseng; Nizar A Mullani; Chusilp Charnsangavej; Timothy Madden; Darren W Davis; David J McConkey; Michael S O'Reilly; Lee M Ellis; James Pluda; Waun K Hong; James L Abbruzzese
Journal:  J Clin Oncol       Date:  2002-09-15       Impact factor: 44.544

8.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

Authors:  Peter Schmid; Sylvia Adams; Hope S Rugo; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Roberto Hegg; Seock-Ah Im; Gail Shaw Wright; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Roel Funke; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens
Journal:  N Engl J Med       Date:  2018-10-20       Impact factor: 91.245

Review 9.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

10.  A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer.

Authors:  Johanna Wagner; Maria Anna Rapsomaniki; Stéphane Chevrier; Tobias Anzeneder; Claus Langwieder; August Dykgers; Martin Rees; Annette Ramaswamy; Simone Muenst; Savas Deniz Soysal; Andrea Jacobs; Jonas Windhager; Karina Silina; Maries van den Broek; Konstantin Johannes Dedes; Maria Rodríguez Martínez; Walter Paul Weber; Bernd Bodenmiller
Journal:  Cell       Date:  2019-04-11       Impact factor: 41.582
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.